What is the recommended treatment for reactive arthritis?

Treatment of Reactive Arthritis

NSAIDs are the first-line treatment for reactive arthritis, with sulfasalazine (2000 mg/day) as the preferred disease-modifying antirheumatic drug (DMARD) for chronic or severe cases that fail to respond to NSAIDs. 1, 2, 3

Initial Management Approach

First-Line Therapy: NSAIDs

• NSAIDs should be initiated immediately for symptomatic relief of joint inflammation, pain, and swelling 1, 4, 5
• Use at the minimum effective dose for the shortest duration possible after evaluating gastrointestinal, renal, and cardiovascular risks 6
• The majority of reactive arthritis cases are self-limited and resolve within weeks to months with NSAID therapy alone 1, 4, 2

Antibiotic Therapy

• Antibiotics are recommended only for active primary infections (urogenital or gastrointestinal), not for the arthritis itself 4, 5
• For post-chlamydial reactive arthritis specifically, prolonged antibiotic therapy (tetracyclines) may provide benefit, though evidence is equivocal 2, 5
• Antibiotics have not proven successful for post-enteric reactive arthritis 2

Treatment for Chronic or Severe Disease

When to Escalate Beyond NSAIDs

Escalate therapy when:

• Symptoms persist beyond 3 months despite adequate NSAID therapy 1, 2
• Severe inflammatory symptoms are resistant to NSAIDs 5
• Approximately 30-50% of cases become chronic and require additional immunomodulatory therapy 4, 2

Second-Line: Sulfasalazine

• Sulfasalazine 2000 mg/day is the only DMARD with proven efficacy in randomized controlled trials for reactive arthritis 3
• A Department of Veterans Affairs study demonstrated 62.3% response rate with sulfasalazine versus 47.7% with placebo (p=0.02) 3
• Well tolerated with mainly nonspecific gastrointestinal side effects 3
• Should be considered the preferred DMARD for chronically active reactive arthritis unresponsive to NSAIDs 2, 5

Glucocorticoid Use

• Systemic glucocorticoids can be used when inflammatory symptoms are resistant to NSAIDs, but should be used at the lowest dose necessary as temporary adjunctive treatment (<6 months) 6, 5
• Intra-articular glucocorticoid injections are appropriate for relief of local symptoms in specific affected joints 6

Third-Line Options for Refractory Cases

For patients unresponsive to sulfasalazine:

• Other DMARDs (methotrexate, azathioprine, cyclosporin) have only sporadic case reports but can be employed in refractory cases 5
• TNF-alpha inhibitors may be effective when reactive arthritis evolves toward ankylosing spondylitis or in aggressive cases, though data are limited and theoretical concerns exist 1, 2, 5
• Only open-label data suggest good efficacy and safety for biologics in reactive arthritis 1

Important Clinical Considerations

Distinguishing Post-Chlamydial from Post-Enteric Types

• Post-chlamydial reactive arthritis: Chlamydial organisms remain viable in the synovium and may benefit from prolonged antibiotic therapy 2
• Post-enteric reactive arthritis: Causative organisms (Salmonella, Shigella, Campylobacter, Yersinia) are generally not viable in joints; antibiotics are not beneficial 2

Monitoring and Follow-up

• Most cases resolve spontaneously within weeks to months, but 30% develop chronic forms requiring ongoing treatment 4
• Monitor for evolution to chronic spondyloarthritis, which may require escalation to biologic therapy 5
• Watch for extra-articular manifestations including enthesitis, dactylitis, and axial involvement 4, 7

Common Pitfalls to Avoid

• Do not use antibiotics to treat the arthritis itself—only treat active primary infections 4, 5
• Avoid prolonged systemic glucocorticoid use due to cumulative side effects; taper as rapidly as clinically feasible 6
• Do not rush to biologics—sulfasalazine should be tried first as it has the strongest evidence base for reactive arthritis 3
• Recognize that TNF inhibitors lack robust trial data in reactive arthritis specifically, unlike other spondyloarthritides 2